Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Report 2022

August 17, 2022

Q1 Report 2022

May 17, 2022

Investor presentations

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Short Report 2018

1 2 3

Press Releases

ObsEva Announces Corporate Updates

press release

July 27, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 –…

Read more

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

press release

June 28, 2022

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back…

Read more

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

press release

June 17, 2022

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back…

Read more
1 2 3 4 5 79

General Meetings

ObsEva Annual General Meeting 2022

May 18, 2022

Read more

ObsEva Annual General Meeting 2021

May 28, 2021

Read more
1 2 3 4

Upcoming Events

Year End 2022 Financial Results week of 06 March 2023

Event


    Read more

    Q3 2022 Financial Results week of 07 November 2022

    Event


      Read more
       

      Contacts

      ObsEva Switzerland Office

      Chemin des Aulx,12

      1228, Plan-Les-Ouates, Geneva, Switzerland

      +41 (0)22 552 3840


      contact@obseva.ch

      Media

      Katja Bührer

      +1 (917)-969-3438

      katja.buhrer@obseva.com

      Investor relations


      .


      Katja Bührer

      +1 (917)-969-3438

      katja.buhrer@obseva.com

      Clinical studies




      clinicaltrials@obseva.ch

      HR Office

      Charlotte Cadoux


      charlotte.cadoux@obseva.ch

      CEO Office

      +41 (0)22 552 1550


      shauna.dillon@obseva.ch

       

      Sign up for news

       
       

        * Type:


        InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












        Read our privacy policy here.


         

        Are you sure you want to leave ObsEva.com?

        We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

        Continue to link

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue